Skip to main content
. 2022 Sep 1;140(9):1009–1019. doi: 10.1182/blood.2021015114

Figure 2.

Figure 2.

Best tumor response in patients with ALK+ ALCL aged <65 years with stage II to IV disease. (A-B) Best response in patients who received CHOP with or without etoposide (A) and in those with ALK− ALCL, AITL, or PTCL NOS regardless of subsequent ASCT (B). Denominators include patients with ALK+ ALCL diagnosed in the period from 2014 to 2018 and treated with either CHOP of CHOEP (A) and patients with ALK− ALCL, AITL, or PTCL NOS diagnosed in the period from 2014 to 2018 and treated with either CHOP or CHOEP (B). PD, progressive disease; PR, partial remission; SD, stable disease; UNK, unknown.